Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: gravity is a force as risks weigh on volatility

October 8, 2020 8:12am

All-time highs scare me in the face of political cross-currents, medical, economic, election rhetoric and uncertainty “issues”

Pre-open indications: 4 SELLs

What I provide is an “intelligence daily” to ensure that shareholders are kept apprised based on a 24-hour surveillance of “our” universe, the RegMed/cell and gene therapy sector and its surrounding markets

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors! My gift to you, I've kept RMi subscription FREE during these COVID-19 and volatile times

Dow futures are UP +0.63% (+178 points), S&P futures are UP +0.43% (+15 points) and NASDAQ futures are UP +0.558% (+67 points)

U.S. stock index futures were higher yet, fluctuating on Thursday as investors await updates on the ongoing fiscal stimulus “talks’;

European stocks traded higher as the pan-European Stoxx 600 climbed 0.6% in early trade;

Asia-Pacific stocks were mostly higher, but Hong Kong lagged with the MSCI’s broadest index of Asia-Pacific shares outside Japan adding 0.71%

Data Docket: initial jobless claims number, which will be released at 8:30 a.m. ET. Economists polled are expecting first-time claims for unemployment insurance to total 825,000 for the week ending Oct. 3. This would mark a slowdown from the 837,000 first time claims for the previous week.

Henry’omics:

The Dow on Wednesday posted its best day in months as …

All of the major averages are higher for October, clawing back some of September’s losses, which was the first negative month since March.

Wednesday night’s post: RegMed Investors’ (RMi) closing bell: go with the flow until it ceases

The Nasdaq closed UP +209.99 points (+1.88%);
The IBB closed up +2.26% and XBI closed up +3.20%
Sector volume was the usual LOW with 8 of the 26-upside having higher than the 3-month average volume with the increased volume of 0 of 7-downside having higher than the 3-month average volume;
The CBOE Volatility Index (VVIX: INDEX) was down -1.42 points or -4.82% at 28.06;
Wednesday’s percentage (%) of the 26-upside were +0.54% (CLBS) to +13.18% (NTLA) while the 9-downside ranges from -0.31% (BLFS) to -6.18% (SLDB);

Q4’s October, so far: 2 positive and 3 negative closes

Q3: July through September: 1 neutral, 28 positive and 34 negative closes with 2 holidays

Companies in my headlights – It’s your decision; I provide an idea and context:

Maintaining Sell:

Biostage (BSTG) closed down -$0.09 to $1.51 after Tuesday’s -$0.01 to $1.60 <after being up +$0.28> after Monday’s +$0.01 to $1.61, Friday’s +$0.03 to $1.60 and last Thursday’s -$0.03 to $1.57. Question#1: WHAT Question#1: WHO is managing finances of this public company? WHERE does RMS, the accounting firm “participate” in ascertaining transparency in financials?

SELL into Strength:

CRISPR Therapeutics (CRSP) closed up +$9.96 to $97.68 and has a POSITIVE +$3.32 or +3.40% aftermarket indication. New highs over gene editing Nobel prize are time to sell “some’;

Intellia Therapeutics (NTLA) closed up +$2.77 to $23.78 and has a POSITIVE +$0.92 or +3.87% aftermarket indication. New highs over gene editing Nobel prize are time to sell “some’;

Fate Therapeutics (FATE) closed up +42.48 to $44.04 and has a NEGATIVE -$0.34 or -0.77% aftermarket indication;

Precigen (PGEN) closed up +$0.33 to $4.38 and has a NEGATIVE -$0.03 or -0.68% aftermarket indication;

The BOTTOM LINE: Reiterating, “As I stated yesterday, profit now, a market storm is brewing.”

There is 27 days left to election voting – uncertainty will be an undercurrent!

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.